Challenges and perspectives in surveillance of post-marketing/use

被引:4
|
作者
Fontenele Martins, Mary Anne [1 ]
Coelho Penna Teixeira, Ana Paula [1 ]
机构
[1] Agencia Nacl Vigilancia Sanitaria Anvisa, Brasilia, DF, Brazil
来源
VIGILANCIA SANITARIA EM DEBATE-SOCIEDADE CIENCIA & TECNOLOGIA | 2019年 / 7卷 / 04期
关键词
Health Surveillance; Health Risk; Surveillance of Post-markting Products; Risk Management and Adverse Effects; DRUGS; SAFETY;
D O I
10.22239/2317-269x.01425
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This essay aims to discuss the challenges and perspectives posed for the post-marketing surveillance in Brazil. Based on a non-systematic literature review, some challenges are pointed out, such as: 1) the need to review the post-marketing/use risk management model; 2) the strengthening of work in the Sentinel Network; 3) the systemic analysis of notifications and integration between the information systems and 4) the effective implementation of the product traceability system. Only a few challenges have been brought into the debate, knowing that many others exist for the expansion and improvement of the post-marketing surveillance, considering the dynamics and globalization of the relations of production and consumption in the risk society.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 50 条
  • [31] Post-marketing surveillance of the safety of levofloxacin in Japan
    Yamaguchi, Hiroki
    Kawai, Hitomi
    Matsumoto, Takuyuki
    Yokoyama, Hiroo
    Nakayasu, Toshio
    Komiya, Masahiro
    Shimada, Jingoro
    CHEMOTHERAPY, 2007, 53 (02) : 85 - 103
  • [32] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Yukinori Sakata
    Toshiyuki Matsuoka
    Satoshi Ohashi
    Tadashi Koga
    Tetsumi Toyoda
    Mika Ishii
    Drugs - Real World Outcomes, 2019, 6 : 27 - 35
  • [34] Post-marketing surveillance and adverse drug reactions
    Shani, S
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 1999, 1 (02): : 117 - 119
  • [35] Post-marketing surveillance: a UK/European perspective
    Gough, S
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (04) : 565 - 570
  • [36] RESULTS OF POST-MARKETING SURVEILLANCE PROGRAM ON STREPTOKINASE
    THAYER, CF
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1981, 30 (01): : 129 - 140
  • [37] Post-marketing surveillance of modafinil abuse and misuse
    Smith, DE
    Calhoun, SR
    Galloway, GP
    Romanoff, SJ
    Wolfe, NE
    SLEEP, 2004, 27 : 57 - 57
  • [38] Signal detection in post-marketing surveillance for controlled substances
    Dasgupta, Nabarun
    Schnoll, Sidney H.
    DRUG AND ALCOHOL DEPENDENCE, 2009, 105 : S33 - S41
  • [39] DIFFERENT APPROACHES OF POST-MARKETING SURVEILLANCE - THEIR REALISM AND INTEREST
    SPRIETPOURRA, C
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1979, 25 (02): : 344 - 359
  • [40] Post-Marketing Surveillance with a Biosimilar of Rituximab (Novex ®) in Argentina
    Milone, Gustavo
    Penna, Maria
    Fernandez, Francisco
    Spitzer, Eduardo
    Millan, Susana
    De Caso, Pablo
    Beligoy, Luis
    Argentieri, Daniel
    Pagani, Fernando
    Alonso, Martin
    Streich, Guillermo
    Kurgansky, Nicolas Matias
    Part, Maria del Carmen Rios
    Brandt, Martin Ignacio
    Mari, Susana
    Gomez, Roberto
    BLOOD, 2017, 130